133 related articles for article (PubMed ID: 35772003)
41. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL; Warsame R; Gertz MA; Buadi FK; Lacy MQ; Kumar SK; Dingli D; Zeldenrust SR; Leung N; Hayman SR; Kapoor P; Gonsalves WI; Kourelis TV; Russell S; Go RS; Hobbs MA; Fonder AL; Rajkumar SV; Dispenzieri A
Blood; 2017 Sep; 130(13):1578-1584. PubMed ID: 28807981
[TBL] [Abstract][Full Text] [Related]
42. Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
Sharpley FA; Manwani R; Mahmood S; Sachchithanantham S; Lachmann H; Gilmore J; Whelan C; Hawkins P; Wechalekar A
Br J Haematol; 2018 Nov; 183(4):557-563. PubMed ID: 30095161
[TBL] [Abstract][Full Text] [Related]
43. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
44. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
45. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
[TBL] [Abstract][Full Text] [Related]
46. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.
Angel-Korman A; Jaberi A; Sanchorawala V; Havasi A
Amyloid; 2020 Mar; 27(1):17-24. PubMed ID: 31595786
[No Abstract] [Full Text] [Related]
47. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
Feng J; Huang XF; Zhang CL; Shen KN; Zhang CL; Sun J; Tian Z; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):107-111. PubMed ID: 28279033
[No Abstract] [Full Text] [Related]
48. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
49. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
50. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
51. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
52. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.
Palladini G; Schönland S; Merlini G; Milani P; Jaccard A; Bridoux F; Dimopoulos MA; Ravichandran S; Hegenbart U; Roeloffzen W; Cibeira MT; Agis H; Minnema MC; Bergantim R; Hájek R; João C; Leonidakis A; Cheliotis G; Sonneveld P; Kastritis E; Wechalekar A
Blood Cancer J; 2023 Jan; 13(1):19. PubMed ID: 36697388
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
54. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.
Riva M; Berno T; Cipriani A; Altinier S; Fedrigo M; Noventa F; Adami F
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e970-e974. PubMed ID: 34489209
[TBL] [Abstract][Full Text] [Related]
55. Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort.
Shen KN; Miao HL; Zhang L; Feng J; Cao XX; Li J
Leuk Lymphoma; 2021 Aug; 62(8):1892-1896. PubMed ID: 33602009
[TBL] [Abstract][Full Text] [Related]
56. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
57. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
[TBL] [Abstract][Full Text] [Related]
59. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
60. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
